Lant A
Drugs. 1986;31 Suppl 4:40-55. doi: 10.2165/00003495-198600314-00006.
Oral diuretics are amongst the most widely used drugs in clinical practice today. Their discovery close on thirty years ago remains a major milestone in therapeutic progress. Though originally designed for treating heart failure, diuretics are more commonly prescribed, worldwide, in hypertension than for relief of oedema. Since the introduction of chlorothiazide, diuretic development has passed through a series of distinct stages. The thiazide era was followed by the 'high-ceiling' diuretics, the antikaliuretics and, more recently, polyvalent agents that cause both saluresis and uricosuria. Alongside these synthetic achievements, major advances have occurred in the knowledge of nephron function and ion transport mechanisms. These have acted as stimulus to the design of novel categories of diuretics. The practising clinician thus has a wide range of available diuretics to choose from. The most appropriate choice of an agent aimed at the relief of symptoms with minimal adverse effects requires an understanding of where and how diuretics act within their primary target organ, the kidney. Whereas various procedures, ranging from micropuncture to the study of brush border membrane vesicles, have been utilised experimentally, investigation of the mode and sites of action of diuretics in man has largely depended on application of clearance methodology. Refinements in analytical chemistry have encouraged study of the pharmacokinetic and metabolic fate of diuretics. Taken together, available evidence shows that most diuretics exert their saluretic action from the intraluminal aspect of the renal tubules. The time-course of drug delivery, as well as total quantity of drug transported into the lumen determine the cumulative drug response. Exceptions are muzolimine and the aldosterone antagonists which act at the peritubular membrane. Distinctive stereospecific effects on luminal tubular ion transport occur with indacrinone and etozoline. The clinical use of diuretics often involves concurrent administration with other drugs. The mechanisms involved in a number of the resulting pharmacodynamic and pharmacokinetic interactions have considerable relevance in patient management. Notable examples of these interactions are the blunting of diuretic action by non-steroidal anti-inflammatory agents and the diuretic-induced diminution in the renal clearance of lithium salts.
口服利尿剂是当今临床实践中使用最为广泛的药物之一。大约30年前利尿剂的发现仍然是治疗进展中的一个重要里程碑。尽管利尿剂最初是为治疗心力衰竭而设计的,但在全球范围内,在高血压治疗中比用于缓解水肿更为常用。自氯噻嗪问世以来,利尿剂的发展经历了一系列不同阶段。噻嗪类时代之后是“高效能”利尿剂、抗利钾利尿剂,以及最近出现的既引起利盐又引起利尿酸作用的多价药物。除了这些合成成果外,在肾单位功能和离子转运机制的认识方面也取得了重大进展。这些进展推动了新型利尿剂的设计。因此,临床医生有多种可用的利尿剂可供选择。要选择最适合的药物以缓解症状并使不良反应最小化,就需要了解利尿剂在其主要靶器官肾脏内的作用部位和作用方式。虽然从微穿刺到刷状缘膜囊泡研究等各种方法已用于实验研究,但利尿剂在人体中的作用方式和作用部位的研究在很大程度上依赖于清除率方法的应用。分析化学的改进促进了对利尿剂药代动力学和代谢转归的研究。综合现有证据表明,大多数利尿剂从肾小管管腔内发挥其利盐作用。药物输送的时间过程以及转运到管腔内的药物总量决定了累积药物反应。例外情况是莫唑胺和醛固酮拮抗剂,它们作用于肾小管周围膜。茚达立酮和依托唑啉对管腔离子转运有独特的立体特异性作用。利尿剂的临床使用常常涉及与其他药物同时给药。许多由此产生的药效学和药代动力学相互作用所涉及的机制在患者管理中具有相当重要的意义。这些相互作用的显著例子有非甾体抗炎药对利尿剂作用的减弱以及利尿剂引起的锂盐肾清除率降低。